This is a past event. To see the list of our current events, please click  HERE

Ana Afuera

ENCOD Executive Committee
European Coalition for Just and Effective Drug Policies

She is a political scientist and an activist working more than 10 years focused on Drugs Policy. Currently, she is an Executive Committee member of ENCOD, in the position of chairperson in the Drugs Policy and Institutional Affairs Department. She was on the Committee of La MACA Barcelona and CatFAC (Catalonian Federation of Cannabis Social Clubs), where she developed her capabilities in political impact collaborating with private and public institutions, setting up social actions, developing institutional relations on drug policy matters and contributing in the settlement of proposals of law. 

Narbe Alexandrian

Canopy Rivers

Prior to joining Canopy Rivers, Narbe was a Senior Associate at OMERS Ventures, one of the most prominent technology venture capital funds in Canada. During his tenure, Narbe  helped fundraise for two funds ($520M of capital), sourced and lead multiple debt/equity financings, and acted as a Board Observer for a number of portfolio companies. Prior to OMERS Ventures, Narbe was a Senior Strategy Manager in TELUS’ Internet of Things (IoT) group where he helped launch operational go-to-market strategies to TELUS’ executive leadership team. He has also held roles at Firmex Inc., a leading virtual data room company based in Toronto, and Deloitte LLP, where he held roles in Financial Advisory and C ... (view full description)

Daragh Anglim

Managing Director
Prohibition Partners

Daragh is a highly experienced business and marketing consultant. Over the last 20 years he's worked with some of the worlds biggest brands and has led teams in both the private and public sector. Background in marketing, communications, brand building, change management and sustainability.

Perry Antelman

Abacus Health Products

Perry Antelman, is the Chief Executive Officer of Abacus. He has over 30 years of executive business experience, funding, launching, and growing companies in the chemical and medical technology/pharmaceutical sectors.
Perry leveraged his experience to launch Abacus Health Products and deliver the first-to-market, legal, OTC registered topical pain relief products blended with CBD hemp extract (Cannabis sativa L).

Aras Azadian

CEO, Chairman, and Co-Founder

Utilizing his extensive senior management experience in both financial and bio-technology sectors, Aras co-founded Avicanna with the vision of establishing a bio-pharmaceutical company with a strict focus on medical and pharmaceutical applications of cannabinoids. His expertise in corporate development coupled with his executive experience in the oncology industry have been integral to Avicanna’s thought leadership pertaining to R&D and clinical development. Since 2016 Aras has successfully led a team of executives, scientists and medical professionals across several countries with the vision of vertical integration and a strong company focus on quality controls, scientific vigour and co ... (view full description)

Vivien Azer

Managing Director
Cowen and Company

Vivien Azer is a managing director and senior research analyst specializing in beverages, tobacco, and cannabis sectors. Vivien is the first senior Wall Street analyst to cover the emerging cannabis sector, resulting in notable global press coverage across media outlets such as CNBC, The Wall Street Journal, The Economist, Barron’s and Forbes.  Vivien’s coverage of the tobacco and cannabis sectors earned her industry accolades including a spot on Institutional Investor’s All-America Research Team on several occasions. She was also named to MJBiz Daily’s list of “20 Women to Watch in 2019” and selected by Business Insider as a “Rising Star of Marijuana Investing.” Viv ... (view full description)

Prof. Mike Barnes

Chief Medical Officer

Mike Barnes has worked in the cannabis field for over 15 years. At first he was involved with the development of Sativex but more recently with the media campaign to change UK law for medical cannabis. He was the first license holder for the boy with resistant epilepsy, Alfie Dingley, who was instrumental in changing politician's minds. He continues to campaign for greater access to medical cannabis. He is Chief Medical Officer of ECH and is mainly involved with the first Medical Cannabis Clinics and the Academy of Medical Cannabis, which is a free on-line teaching programme. 

Crispin Blunt

MP for Reigate & Co-Chair
All Party Parliamentary Group for Drug Policy Reform

Crispin Blunt was educated at Wellington College, Royal Military Academy Sandhurst (Regular Commission 1979-90), University of Durham (BA Politics) and Cranfield School of Management (MBA, 1991). In 1992 he unsuccessfully stood for Parliament as the Conservative candidate for West Bromwich East. In 1993 Crispin was appointed Special Adviser to Malcolm Rifkind, as Secretary of State for Defence (1993-95) and Foreign Secretary (1995-97).     Crispin was elected to Parliament for Reigate in Surrey in May 1997. Since 1997 he served on the Defence and Environment Select Committees before being a front bench Conservative spokesman on Northern Ireland (2001-2); Trade, Energy and Science ... (view full description)

Rick Brar

CEO & Chairman
Brains Bioceutical Corp.

Rick Brar was most recently Co-Founder and Former CEO of Zenabis Global Inc., one of the leading Canadian LPs with operations in both medical and recreational cannabis.  Under Brar’s leadership, Zenabis grew from a privately held LP to a public company with a market capitalization close to CAD900m during his tenure as CEO. Brar plays an active role in the Cannabis regulatory environment and he has worked to improve access globally, from being a part of the ACPMR Stakeholder Roundtable for Bill C45, held by Health Canada, to holding positions with the Centre for Medical Cannabis (CMC) and the CDPRG.  He has successfully launched multiple entrepreneurial ventures in Nor ... (view full description)

Alex Brooks

Senior Analyst
Canaccord Genuity

Alex Brooks is a senior analyst at Canaccord Genuity, covering UK-listed materials technology, energy services, and medical cannabis companies. He has covered a wide range of industrial & energy companies over twenty years in the City, working on projects from large-scale emerging market IPOs to small secondary fundraises. He started his career at JPMorgan Asset Management, and has also worked sell-side at UBS & Credit Suisse.

Dr. Christian Cardona

Minister for the Economy, Investment and Small Businesses
Government of Malta

The Hon. Dr. Christian Cardona was born in 1972 and graduated as Notary Public and Doctor of Laws from the University of Malta. Prior to his appointment as Minister for the Economy, Investment and Small Businesses, Dr. Christian Cardona was a Senior Partner at CV Advocates. Dr. Christian Cardona was first elected to Parliament in 1996 and was re-elected in the 1998, 2003, 2008, 2013 and 2017 general elections.  In 2016, he was elected as Deputy Leader for Party Affairs for the Labour Party. 

Michael Corcoran

Hill Dickinson

Michael is a Partner in the Corporate Team at Hill Dickinson LLP and has helped established Hill Dickinson, and in particular its health and regulatory team, as one of the leading law firms in the UK advising medical cannabis companies. Michael led the team advising AIM listed FastForward Innovations Limited (FFWD) on the first two investments by an AIM company in the medical cannabis sector, and has since advised a number of European and North American companies investing in and developing medical cannabis business in Europe. Historically Michael has advised high growth private and listed companies, particularly in the technology, life-sciences and resources sectors. Michael has extensive c ... (view full description)

Nick Davis

Chief Executive
Memery Crystal

Nick Davis is the Chief Executive of Memery Crystal and a Senior Partner in the firm’s Corporate team.Memery Crystal are the leading UK law firm on advising the emerging cannabis sector on business set-up, capital markets, mergers and acquisitions, private fundraising, licencing and commercial contracts. Nick is currently advising a number of cannabis companies and recently led the Memery Crystal team on the NEX listing of medicinal cannabis investment vehicle Ananda Developments - the second ever public listing of a cannabis vehicle.Nick firmly believes we are in a new era for the cannabis sector, with a strong pipeline of companies looking to list in Londo ... (view full description)

Navdeep Dhaliwal

The Supreme Cannabis Company Inc

Navdeep Dhaliwal is an entrepreneur, financier and investor focused on ventures and initiatives that create positive global change. He has extensive knowledge and experience across industries including cannabis, renewable energy and technology. Mr. Dhaliwal is Chief Executive Officer and a Director of The Supreme Cannabis Company, Inc. He believes that cannabis legalization is a global game-changer that will have a positive impact socially, medically and as a recreational product. Mr. Dhaliwal is also a Director of Medigrow Lesotho, a Licensed Producer in the Kingdom of Lesotho. Prior to joining Supreme Cannabis, Mr. Dhaliwal was the Principal of NLX Capital Corp., a Canadian mer ... (view full description)

Arnaud Dumas de Rauly

Chief Executive Officer
The Blinc Group

Arnaud is currently the Co-founder and CEO of The Blinc Group, a company founded to innovate, manufacture and distribute safe, consistent vaping products. Arnaud leads and evaluates operations of the company through international marketing, communication and public relations. Arnaud also serves as the Chair of the ISO Standards Committee on Vapor Products and the CEN Standards Committee on Vapor Products.

Nic Easley

CEO & Managing Director
Multiverse Capital

Nic Easley is a globally recognized cannabis industry expert and a sought-after writer, panelist, and keynote speaker for many top conferences and publications. He is the CEO and Managing Director of Multiverse Capital™, a cannabis venture firm, and the founder and CEO of 3C Consulting, LLC, the leading global strategic cannabis consulting firm. Nic and his team have worked in 16 countries, 34 U.S. States, and two territories assisting nearly 500 cannabis companies across all sectors of the industry. He is known for his passionate commitment to introducing demonstrated best practices from other industries into the cannabis space. His industry-leading track record of building stro ... (view full description)

David Elsley

Cardiol Therapeutics

David Elsley, President and CEO, Cardiol Therapeutics   Mr. David Elsley is a business leader with a proven track record of developing, financing and managing all aspects of corporate development in biotechnology and high-growth organizations. He founded Vasogen Inc., a biotechnology company focused on the research and commercial development of novel therapeutics for the treatment of heart failure and other inflammatory conditions that reached a market capitalization of over US$1 billion.   Mr. Elsley managed and directed Vasogen’s growth from start-up to an organization employing over 250 people, with operations and R&D programs in Canada, the United States and E ... (view full description)

Dean Gainsley


Tristan Gervais

Head of European Medical Cannabis Investment Banking
Canaccord Genuity

Tristan Gervais established Canaccord Genuity’s European Medical Cannabis Investment Banking team in July 2018. Tristan is also a Global Ambassador of First Wednesdays, the European Cannabis Professional Network. Tristan specialises in Private Placements and joined Canaccord Genuity in 2017 as Head of Private Capital Coverage. Tristan has 18 years’ experience providing Investment Banking solutions to this unique pool of private capital across EMEA. Previously, he was Executive Director, Global Family Office at UBS AG and also provided M&A Advisory for family and entrepreneur-owned businesses across EMEA at Deutsche Bank and JP Morgan. Tristan graduated from King's College Lon ... (view full description)

Mazen Haddad

LGC Capital

CEO since March 2019. Over 20 years experience in building companies from an early stage. Most of his experience emanates from the venture capital space ranging from companies both in the US and Canada to real estate and mining. He is also a co-founder of LGC Capital.

Paul Henderson

Grupo Flor

Paul’s corporate career spans 20 years with vast experience in leading Operations, Business Development, Distribution, Product Management, and Finance departments,  He led a team at Goldman Sachs during the bank’s launch of GS Bank USA taking the operation from concept to $24B in assets in less than 24 months.  At GE Capital he worked on high visibility projects like raising institutional capital for the real estate business, creating partnerships in the alternative fuel space with large automotive fleet manufacturers, and restructuring an entire sales and support organization.  Then at Apple he was responsible for all global education and enterprise finance programs un the Apple Financial S ... (view full description)

Darryl Jones

Isracann BioSciences

Darryl Jones has over 15 years of capital market experience with a well-established financial network. Prior to joining Isracann in 2018, Mr. Jones was an investment advisor with PI Financial Corp Canada. At PI Financial, heraised seed capital and took True Leaf Medicine public in early 2014 at $10MM valuation and exited in 2016 at $150MM market capitalization. Mr Jones also worked at Raymond James Ltd Canada where he was involved in structuring and financing well over 20 acquisitions from medical to health sciences to mineral exploration in agnostic platform deals. Mr. Jones currently serves on several other public company boards including Strikepoint Gold and Voltaic Minerals Corp.

Rob Kampia

Executive Director
Marijuana Leadership Campaign

Rob previously co-founded the Marijuana Policy Project in 1995 and served as its executive director for 23 years, leaving MPP in 2017 to found the Marijuana Leadership Campaign, which is based in Austin and Washington, D.C. Rob grew up in the suburbs of Philadelphia in Harleysville, Pennsylvania. In 1986, he graduated as valedictorian of his class at Souderton Area High School, and in 1993 he graduated with honors from Penn State University with a bachelor’s degree in Engineering Science and a minor in English. In the middle of his seven-year tenure at Penn State where he had a full scholarship, he served three months in a county prison near State College after being ... (view full description)

Matt Karnes

Founder & Managing Partner
GreenWave Advisors

Matthew (Matt) Karnes has over 20 years of diverse finance and accounting experience. Prior to founding GreenWave Advisors LLC in 2014, Matt worked in equity research focusing on the Radio Broadcasting and Cable Television industries for First Union Securities. Matt also covered Satellite Communication at SG Cowen and in addition, worked with the top ranked Consumer Internet analyst at Bear Stearns & Co – this team was consistently recognized by the Institutional Investor’s “All America Research Team”.  As a sellside equity analyst, Matt authored and co-authored numerous emerging industry research reports including such names as Google, Sirius, XM Satellite Radio, DIRECTV and EchoStar Co ... (view full description)

Kris Krane

President & Co-Founder 4Front
Cannex Capital

Kris Krane founded 4Front in 2011 and now serves as president of 4Front. Prior to forming 4Front, Kris served as director of client services for CannBe, a pioneer in developing best practices within the medical cannabis industry. Kris has dedicated his career to reforming the nation’s misguided drug policies, having served as associate director of NORML from 2000 to 2005 and executive director of Students for Sensible Drug Policy from 2006 to 2009. He currently serves on the National Cannabis Industry Association board of directors.

Dan Kriznic

Co-Founder & Business Development
Winchester MD

Dan Kriznic has founded and co-founded a number of successful private and public companies in emerging markets with more recent involvement in Cannabis in Canada, US, Jamaica, Peru and Europe.Collectively he has been responsible for 9 public listings, $243 million in M&A transactions, $175 million in financings and $281 million in value for shareholders from selling companies. Dan founded High Standard after recognizing a need for financial and advisory services in fast growing emerging sectors.  He is the former CEO, Chairman and founder of Invictus MD Strategies (TSXV: GENE; OTC: IVITF) where he spearheaded over $62 million in acquisitions and raised over $115 million in fi ... (view full description)

Pavel Kubu

International Cannabis and Cannabinoids Institute

Pavel Kubu MD is the expert in the fields of medical informatics and adictology. In 2001, graduated in general medicine with a focus on diseases prevention at Charles University in Prague, 3rd Medical Faculty. Since 2005 to 2015 worked for Intel Corporation as the Business Development Manager leading projects for Healthcare and Education in Central and Eastern Europe. In 2006 apointed as chairman of the Ethical Commission of the National Monitoring Center for Drugs and Drug abuse of the Czech republic goverment. Serves since 2007 as the board member of the Czech National Forum for eHealth where he is focused on research and development of new treatment and preventive method ... (view full description)

Steve Malloy

PharmaRolly Holdings BV

Mr. Malloy is the founder and CEO of PharmaRolly Holdings B.V.  PharmaRolly has obtained Federal approval to cultivate medical cannabis and is actively developing a facility in Europe for export. The facility has over 1 million square feet of land for greenhouse grow together with an over 40,000 sq feet building for fully indoor, cultivation and extraction of medical THC & CBD products in accordance with GMP standards.  PharmaRolly expects to commence cultivation operations shortly.

Nicole Marchand

Grit Capital

Graduated from Wilfrid Laurier University with an Honors of Bachelors of Business Administration with co-op (BBA) in 2005. Vast capital markets experience with roles in institutional sales, investment banking, and over 8 years in investor relations. Started career in investment banking working for boutique, Blair Franklin as well as Scotia Bank, focusing on Mergers & Acquisitions. Later working at an independent boutique in institutional sales covering Toronto & Vancouver Founded her own firm, Auburn Partners Investor Relations Firm Founder of Love Puppies Non-for-profit with the mission to end Puppy Mills in Canada Nicole is ... (view full description)

Thomas Mazarakis

Portfolio Advisor
Salveo Capital

Tom Mazarakis is a Portfolio Advisor at Salveo Capital, a venture capital fund focused exclusively on the legal cannabis industry.  The Fund has a diversified portfolio that spans ancillary service providers to the industry as well as plant-touching companies.  Tom has over 18 years of Wall Street investment experience and was a Managing Director at Goldman Sachs where he ran the Fundamental Strategies Group of research analysts for almost 10 years.  Tom graduated from Northwestern University with a BS in Environmental Engineering and received an MBA from the University of Michigan.

Peter McCullagh

Founder & Managing Partner
TenX Ventures Inc

Peter has over 35 years’ experience as a successful entrepreneur, business executive and thought leader with > $9B in exits.  Prior to founding TenX Ventures, he spent ~ 10 years growing and helping to sell 3 companies:  Mysis plc which was sold in two parts for $3.2B, Siebel Systems Inc., sold to Oracle for $5.9B, and e-Chemicals Inc., which was sold to Aspen Technology.  Before this, McCullagh was a partner at PriceWaterhouseCoopers, a banker at Scotiabank, and started and ran numerous start-ups beginning in his teen years.     He is currently Founder and Managing Partner at TenX Ventures Inc., a Vancouver based, Hands On, Early Stage Venture and Advisory firm that backs passionat ... (view full description)

Fraser McGee

General Counsel
Winchester MD

Fraser McGee is a UK qualified solicitor and specialised in corporate finance and investment fund work with prominent City law firms before moving to work in in-house with investment banks. After working as general counsel at the globally focused hedge fund RAB Capital plc with the Special Situations, Energy and Technology Funds Fraser became the CEO of an AIM quoted natural resources business, partnering with the Majors before setting up an independent consultancy business to provide general counsel services to the alternative investment sector. That work extended to the European medical cannabis space from the early part of 2018 and included working with networks of entrepreneurs, professi ... (view full description)

John McMullen

LGC Capital

He has over 20 years experience in international capital markets. His focus is on micro and small cap public companies. Cannabis industry thought leader and enterprise builder. Twitter: @Jadmcmullen

Molly Meacher

APPG for Drug Policy Reform

Baroness Meacher has been Chair of the All-Party Parliamentary Group for Drug Policy Reform since 2011 Baroness Meacher was educated at the Berkhamsted School for Girls, the University of York, and the University of London. Baroness Meacher has held a number of senior management roles, and worked as a senior adviser to the Russian Government on employment in the 1990s. She has been the author and editor of books on mental health and poverty. She has served as deputy chair of the Police Complaints Authority and Chair of the Security Industry Authority. She was Chair of the East London NHS Foundation Trust until 2012. On 2 May 2006, she was made a life peer, of Spitalfi ... (view full description)

Farzad Moshfeghi

Winchester MD

Farzad is a Physics graduate from the University of Manchester Institute of Science and Technology. He has 30 years experience working for large organizations such as JPMorgan, Goldman Sachs, Merrill Lynch, Credit Suisse and Barclays Capital specializing in derivatives pricing, risk management and regulatory reporting. He spent 2.5 years at Otsuka pharmaceuticals Europe - A Japanese company focused on mental health advising them in Transparency, Compliance and regulatory reporting. Farzad is also a founder of Finity Asset, specializing in advising junior mining and oil & gas companies raise funding. Farzad has been responsible for the commercial development of Winchester MD (Former ... (view full description)

Will Muecke

Managing Member
Artemis Growth Partners

Will Muecke is a co-founding managing member of Artemis Growth Partners, an impact-oriented private equity platform dedicated to investing 100% in the cannabis industry on a worldwide basis.  Artemis Growth Partners oversees US $150+ million in discretionary assets under management (AUM) invested in the global cannabis supply chain, including branded products, distributors, value-added service providers, ancillary operators, and science-driven research and development platforms. Will is also co-founding managing partner of CoreCo Private Equity, a 2017 GIIRS-rated "Best for the World" impact fund backed by investors including the IFC/World Bank, and the multilate ... (view full description)

Stephen Murphy

Co-Founder & Group Managing Director

Stephen is Co-Founder and Group Managing Director of ECH an unrivalled group of companies at the forefront of the medical cannabis industry. As a cannabis specialist focused on developing the legal European cannabis industry, Stephen is also the co-founder of Prohibition Partners and of Cannabis Europa. With a background in technology, digital media and corporate finance, Stephen works with investors, entrepreneurs and regulators to identify, qualify and maximise the opportunities in this emerging frontier.

James O'Dowd

Secretary General
European Alliance for Medicinal Cannabis (EAMC)

James established the European Alliance for Medicinal Cannabis (EAMC) in February 2019 with the central aim of promoting a sensible policy towards medicinal cannabis in the EU27. With a new European Commission and a new European Parliament taking office this year, EAMC is the Brussels based vehicle through which the industry can speak with a unified voice. With the industry finding its feet in Europe, EAMC aims to avoid the imposition of regulatory barriers that may adversely affect the growth of the market. EAMC aims to ensure the legislative process preserves the interest of its members as well as the interests of consumers and patients throughout Europe. In his capacity as Man ... (view full description)

Justin Ort

Measure Eight Venture Partners

Justin Ort is the CEO of Measure 8 Venture Partners, LLC and the CIO of the firm’s hedge fund, Measure 8 Full Spectrum, LP.  Mr. Ort has over 25 years of experience in the asset management industry. Prior to co-founding Measure 8 Full Spectrum fund, Mr. Ort was the head of Domestic Equities at FNY Investment Advisors, LLC and a member of its advisory board. As a Senior Partner, Mr. Ort managed the largest allocation of any trader at FNY and has significant experience in cannabis and risk arbitrage investing.
Mr. Ort graduated from Williams College with a BA in Economics.

Alfredo Pascual

International Analyst
Marijuana Business Daily

Based in Germany, Alfredo works as International Analyst for Marijuana Business Daily, focusing on international cannabis markets and regulations. He has an academic background in business and public policy. Before joining MJBizDaily, he founded Transnational Cannabis, a regulatory consultancy firm that had clients in Europe and Latin America. Previously, he did business development for ICC Labs with a primary focus on developing expansion opportunities internationally.

Emily Paxhia

Managing Director

Emily Paxhia is a co-founder and Managing Director of Poseidon. Emily has reviewed thousands of companies in the cannabis industry and has worked with countless founders in many capacities ranging from their pitch preparation, go-to-market strategies/product launches to business operations. She holds seats on the boards of directors for portfolio companies and participates as an advisor to multiple teams. Emily also serves on the Board of MTech Acquisition Corp. Emily is very active in the investment decision making and ongoing investment oversight processes working closely with her partners to source investment opportunities,  create meaningful deal structures and to ensure that ... (view full description)

Marco Perduca

Co-Founder/ Co-ordinator
Science for Democracy/Associazione Luca Coscioni

Mr. Perduca was a senator in Italy from 2008 to 2013, serving on the Foreign Affairs, Justice, and Human Rights committees. For 20 years, he has coordinated the activities of the Nonviolent Radical Party at the United Nations (UN) in New York, as well as in Geneva, Switzerland, and Vienna, Austria, and has organized high-level meetings to abolish the death penalty in Africa and Central Asia. He has also collaborated with British law firms and various American foundations on ending human rights violations in Italy. Mr. Perduca is an expert on UN mechanisms, with an emphasis on drug policy reform. In April 2018, he cofounded the international platform Science for Democracy, of which he is curr ... (view full description)

Tahira Rehmatullah

T3 Ventures

Tahira Rehmatullah is President of T3 Ventures Advisory and member of the board of directors for Akerna Corp and Superette. From brand building to hedge funds, Tahira has previously held positions at Hypur Ventures, MTech Acquisition Corp., Marley Natural, Privateer Holdings, City First Enterprises, Perry Capital, and Ernst & Young. She is an investor and advisor to numerous cannabis businesses and entrepreneurs, including the advisory board of The Initiative and the Last Prisoner Project, and is dedicated to developing female and minority leadership in the industry. Tahira earned her MBA from the Yale School of Management and B.S. in Finance from The Ohio State University. She resides i ... (view full description)

Tomas Sadilek

Director of Government Affairs
International Cannabis & Cannabinoids Institute (ICCI)

Tomas Sadilek joined the ICCI in the position of Director of Government Affairs. He brings with him extensive experience from the Office of the Government of the Czech Republic in the field of Legal and Illegal Drugs. Tomas represented the Czech Republic in all drug-related meetings in the United Nations institutions (Vienna, New York). Furthermore,  he represented the Czech Republic in meetings in the EU area, Eastern Partnership countries area, occasionally the US; these being related to UN meetings, Council of the EU meetings and Council of Europe meetings.

Jennifer Sanders

Founder & CEO
CNS Equity Partners

With CNS Equity Partners and AURA Venture Funds, Jennifer leverages her expertise in the alternative agriculture and holistic health industries as a corporate consultant for institutional firms and investments.   As a  founder of CNS Equity Partners, a virtue-based private equity firm, she launched the nation’s first holistic health and cannabis herbal retailer. The fully integrated retailer, The Green Heart, is actively franchising  across the United States. A Harvard University Business School graduate, Jennifer specializes in international investment regulatory compliance and enterprise risk management with over 15 years of experience in leadership and business management. She has t ... (view full description)

Joel Sherlock

Chairman & Co-Founder
Vitalis Extraction Technology

A serial entrepreneur and business leader, Joel is a born connector who has been building great teams and delivering the expertise to execute. Joel has been at the helm of 9 successful start-ups and corporate exits, including one of BC’s top private real estate brokerages, a national first action sports e-commerce company, a successful corporate consulting firm and a few private equity funds. Joel’s time is now focused on Kelowna, BC-based Vitalis Extraction Technologies, an industry leader in manufacturing industrial supercritical CO2 extraction equipment, where he is Chairman and Co-Founder, as well as on Spectrum Asset Leasing and Doventi Capital. Doventi Capital in Vancouver is the ... (view full description)

Kiran Sidhu


Kiran is a seasoned cannabis executive, serial entrepreneur and former M&A banker.  Kiran has been Director of Halo Labs since September 2018 and its CEO since 2016, developing a leading company in cannabis extraction that utilizes every type of extraction and producing over 4 million grams of product since inception. Prior to cannabis, Mr. Sidhu was the Chairman, CEO and Founder of Transact Network, a leading EU electronic money institution which was sold to Bancorp (NYSE:TBBK) in 2011. Kiran was previously the CFO of On Stage Entertainment (NASDAQ:ONST) which he help lead to a NASDAQ IPO. Previously worked at PwC in the strategic consulting group and with Merrill Lynch Capital Markets ... (view full description)

Hannah Simon

Managing Director
The Medical Cannabis Clinics

Hannah Simon is the Chief Operating Officer of European Cannabis Holdings (ECH Limited), which has played an integral role in the launching of the UK’s first network of specialist medical cannabis clinics, namely The Medical Cannabis Clinics. Hannah recently oversaw the opening of the first of these clinics in Greater Manchester, and is launching its flagship London clinic this month, with several more planned up and down the country during the course of 2019. These multidisciplinary private medical clinics will offer innovative cannabis treatment to patients who have not found existing treatments to be effective.

Rod Stephan

Altitude Investment Management

Roderick C. Stephan has broad experience in starting and growing investment fund management businesses over his 30-year financial career. Rod is a founding partner of Altitude Investment Management LLC,  a management company managing cannabis investments in North America and Europe. As a mentor and advisor  to early-stage and growth cannabis companies, he sits on a number of corporate boards. He was previously  a founding partner of Longacre Fund Management (UK) LLP, a London-based alternative investment adviser managing over  $300 million in assets (2006-2010) and co-founder of the of the Distressed Investments Group at Citadel Investment Group (“Citadel”) in 1999 and head ... (view full description)

Colin Stott

ABC Clinics

Colin is a veteran of the UK cannabis-based / cannabinoid medicines industry. As R & D Operations Director at GW, Colin was closely involved in the approval of Sativex, GW’s first cannabis-based marketed product, and the more recently NDA-approved cannabinoid (CBD) medicine for treatment-resistant epilepsy, Epidiolex, and a key individual in the development of GW’s discovery and development pipeline, until 2017. As Scientific Affairs Director, he was part of the Medical Affairs team responsible for the preparation for launch of Epidiolex in the international region (ex-US). Colin has more than 25 years’ experience in preclinical & clinical development with specific ... (view full description)

Drake Sutton-Shearer


Drake Sutton-Shearer is the CEO and Founder of PRØHBTD, a hybrid consumer goods and content company. With a mission to lead cannabis from the black market to the supermarket, PRØHBTD creates and markets lifestyle and wellness brands to global consumer audiences, overturning the taboos and stereotypes of the status quo cannabis vernacular and continually pushing it toward the mainstream. As a serial entrepreneur, Drake previously founded a Grammy-winning talent management firm with multi-platinum creative clients and a lifestyle branding and marketing consultancy that serviced premier companies including Warner Bros, SONY, Universal, Microsoft, Budweiser, Walmart, Pepsi, Amazon, Target, ... (view full description)

Karan Wadhera

Managing Partner
Casa Verde Capital

Karan Wadhera is the Managing Partner at Casa Verde Capital, the leading venture capital firm in the cannabis industry. Karan leads the team across investment strategy, fundraising, and portfolio management; he also sits on the board of 11 cannabis companies. During his tenure at Casa Verde, Karan has been responsible for raising the $45mm fund and deploying across 15 portfolio companies, which have collectively raised over $250mm in funding. As an established thought leader in the space, Mr. Wadhera has been featured in numerous mainstream press outlets and conferences, including the Milken Global Conference, CNBC, Bloomberg, TechCrunch, Financial Times, and more.     Prior to C ... (view full description)

Roby Zomer

Executive Director & CTO
MGC Pharmaceuticals

Mr. Zomer holds over 10 years of experience in the BioTech and AgroTech sectors alongside running large scale projects, he co. found MGC Pharmaceuticals as and joined as Executive Director & CTO, bringing his extensive business contacts, scientific and engineering skillset to bear on ensuring MGC’s position as a leader in research and development, as well as ensuring top performance from our global operations. His recent appointment to Managing Director follows successful implementation of MGC’s pipelines as leading global Bio-Pharma company and indicates MGC’s commitment to scientific leadership. 
Sign In
Sign in with LinkedIn
Contact Information
1120 Avenue of the Americas, 6th Floor
New York, NY 10036 USA

Phone: +1 (212) 901-0506
(8:30 AM - 5:30 PM Eastern Time / Monday-Friday)


Event Contacts for IC3 - The Inaugural Institutional Capital & Cannabis Conference (Europe)


Below are the terms and conditions governing your use of Euromoney USA LLC ("IMN") this website and any products or services connected therewith. By using the website or services connected with the website, you acknowledge and agree to the following:

*Your Obligations. You represent and warrant that you have the capacity to agree to these Terms and you are at least eighteen (18) years of age. To the extent any individual accesses a Site or uses a Service as an employee, partner, director, agent or representative ("Agent") of any legal entity which is a Subscriber, the Agent warrants that he or she has authority to agree to these Terms on behalf of the relevant legal entity.

You will procure that you and any licensed user under your subscription will: (a) comply with all applicable laws in relation to the site and services, including without limitation, laws relating to the use of Intellectual Property; (b) not use the site or the content outside the scope of permitted use and will not infringe any Intellectual Property or other rights in or relating to the site or the services or of any third party; (c) not copy, reproduce, recompile, decompile, disassemble, reverse engineer, upload, download, transmit, create derivative works from or otherwise exploit or tamper with the site or any software embodied in any site or service; (d) not prevent or restrict the use of any site or service by other authorized users nor hack into or cause damage to any server or other equipment operated by us; and (e) comply fully with these Terms.

*No IMN Warranties or Representations. IMN makes no warranty, express or implied, concerning any use of this website or any service or product provided in connection with this website. The services and products provided by IMN are provided on an "AS IS" basis. IMN disclaims any implied warranty of merchantability or fitness for a particular purpose, including any warranty for the use or the results of the use of the products or services. IMN is not responsible for correcting, maintaining or updating the data and services made available on this website.

Any material and analysis provided by or through IMN or this website is not a recommendation that must be followed or an offer, or solicitation of an offer to buy or sell any financial product; IMN does not recommend that you enter into a particular transaction or represent that any product or service described on this website is suitable for you or your company. Nor is any information displayed here promoting any particular financial product, service or trading strategy in any jurisdiction where such an offer or solicitation, or trading strategy may be prohibited. As all prudent investors know, some transactions, including but without limitation, those involving high-yield securities, give rise to substantial risk and any investment decision you may make is your own. You should not enter into any transactions unless you have fully understood all such risks and have independently determined that such transactions are appropriate for you. Any discussion of the risks contained herein with respect to any product should not be considered to be a disclosure of all risks or complete discussion of the risks mentioned.

*Restricted Use. As a user of this website, you are not permitted to display, modify, copy, print or otherwise use the information made available to you here only for your own use. You are not permitted to publish, transmit, or otherwise make this information available in any format to any third party without the prior express written consent of IMN. You also are not permitted to change or remove any copyright (©), trademark (®, SM, TM) any other notices displayed with the information. IMN can modify the information at any time and for any reason at its sole discretion. Unless expressly stated otherwise herein, no rights are granted to you regarding the information on this website from IMN or any other source, including third party providers of information for this website, which shall under no circumstances be liable to you in any way.

*IMN Monitoring. Your use of the products and services on this Web site may be monitored by IMN in any lawful manner, and that the resulting information may be used by IMN for its internal business purposes or in accordance with the rules of any applicable regulatory or self-regulatory organization.

*Website or Internet failure. IMN shall have no liability, contingent or otherwise, to you or to third parties, or any responsibility whatsoever, for the failure of any connection or communication service to provide or maintain your access to this service, or for any interruption or disruption of such access or any erroneous communication between IMN and you. IMN also does not warrant or represent that the website shall be completely secure, specifically including without limitation, that no unauthorized person shall intercept or access information transmitted by you.

*Website Access. Access to this website is restricted by password and only authorized IMN registrants may use the website. Any unauthorized access shall be the responsibility of the Registrant and his or her company and IMN shall not be liable for any damages arising out of such unauthorized access. You agree to: (1) Keep your password confidential; (2) prohibit others from using your account; (3) refrain from using other Users’ accounts; (4) refrain from selling, trading, or otherwise transferring your account to another party; and (5) refrain from charging anyone for access to any portion of DirectConnect, or any information arising therefrom. You are also responsible for anything that happens through your account unless you can demonstrate that your account was accessed without your knowledge or fault.

*User Communication. To the extent permitted while using DirectConnect, you can use and participate in groups, free to post and delete comment on the website. You are solely responsible for your interactions with other users. IMN may limit the number of connections you may have to other users and may at its sole discretion prohibit you from contacting other users through use of the Services or otherwise limit your use of the Services.

If you violate this Agreement while posting, that content may be removed without further notice or the rights of others posting here. Nothing you post here is confidential or proprietary and you are cautioned that other posters or viewers may use any information posted here. By posting here you agree that IMN is not responsible for the misappropriation or misuse of any information posted on this website.

*Privacy. Any submissions, including private personal information, like names, addresses and so on, are voluntary and you waive any and all rights you have to the protection of that information. By submitting ideas, suggestions, documents or other matter ("Submissions"), you agree that: (a) the Submissions are not confidential or proprietary information; (b) IMN has no obligation to keep the submissions confidential; (c) IMN can use or disclose the Submissions for any purpose, in any way, in any media worldwide; (d) if asked, you will irrevocably assign to IMN all rights to your Submissions; and (f) you are not entitled to any compensation of any kind from IMN under any circumstances.

*Content by Becoming a User of DirectConnect: As part of obtaining registration access to DirectConnect, unless you opt out, you may receive invitations to network from other conference attendees. We may also send you emails to keep you updated on developments in the site and services. Your registration for and/or subscription to such an email service and your use of the content received through these email services will be subject to these terms. You can unsubscribe to our email service by changing your email preferences on the website.

*License. If you comply with all your obligations under this Agreement, IMN grants you a limited, revocable, nonexclusive license and right to access the Services, through a generally available web browser, mobile device or application view information and use the web pages and in accordance with this Agreement for your use only. Any other use of DirectConnect is strictly prohibited. All rights not expressly granted in this Agreement, including, without limitation, title, ownership, intellectual property rights, and all other rights are retained by IMN.

*Anti-Hacking. You expressly agree not to use or attempt to use any "virus," "spyware," "malware," "adware," "Trojan horse" "deep-link," "scraper," "bot," "spider," "data-mining," "computer code" or any other automated device, program, tool, algorithm, process, or methodology or manual process having similar processes or functionality, to access, acquire, copy, or monitor any portion of this website or content. You also agree not to obtain or attempt to obtain through any means any materials or information on the website that have not been intentionally made available either by their public display on the Web Site or through their accessibility by a visible link or portal. You further agree not to violate the security of the website or attempt to gain unauthorized access to the website, data, materials, information, computer systems or networks connected to any server, through hacking, password mining or any other method.

*No Linkage. You expressly agree not to link or attempt to link to this website or the web pages contained herein.

*Third Party Information. Some of the information you access here is the property of third parties, made available here with the express permission of those third parties. IMN is not responsible for the content of any third party information provided on this website. You are cautioned that any further use of that information by you may be subject to the rights of those third parties and you may be required to obtain a license to use any such information. Failure to obtain third party permission may be a violation of federal law. You should contact the third party provider of the information to ascertain the requirements for using the information.

*Copyright and Trademarks. The layout of the website pages, graphics and pictures used and the collection of individual contributions are protected by copyright. All copyrights belong either to IMN, the third-party content providers or both. Either IMN or the third-party content providers own all trademarks and service marks depicted here.

*Indemnification. You agree to indemnify hold harmless and defend IMN, including our employees, officers, agents and contractors and our related entities and their employees, officers, partners, agents and contractors ("Indemnified") and continue to keep the Indemnified indemnified from and against any actions, proceedings, claims, demands, costs (on a full indemnity basis including, without limitation, reasonable legal and accounting fees) brought or made against the Indemnified by any person arising in connection with your use of the Website or content, or a breach of your representations and warranties in the Terms and Conditions of Use or this Agreement, or your violation of any of the Terms and Conditions of Use or this Agreement or any other activity in which you engage on or through, and from and against any damage, loss(whether personal or property, and whether direct or consequential, including without limitation consequential financial loss), cost or expense suffered or incurred by any Indemnified as a direct or indirect consequence thereof.

*Changes in Terms and Conditions. IMN may at any time revise the terms and conditions by which you may access the website or use IMN products or services. By using this website and IMN products and services, you agree to be bound by any such revisions and should therefore periodically visit this page to determine the then current version of this document.

*Limitation of Liability. Neither we, nor any of our suppliers, officers, employees, partners, affiliates, subsidiaries, successors and assigns, agents or representatives (our "Representatives") will be liable to you for:

(a) any incidental, punitive, indirect, special or consequential damage, loss or expenses, including but not limited to any loss of business, contracts, revenue, or profits, any business interruption, security breach, loss of data, loss of goodwill or reputation or other pecuniary loss suffered by you, even if we or any of our Representatives have been advised of their possible existence; nor? (b) any direct damage loss or expenses arising from loss of customers, loss of profits, loss of anticipated profits or loss of savings.

*Termination. You may terminate this Agreement, for any or no reason, at any time, when IMN receives notice from you. IMN may terminate the Agreement and your account for any reason or no reason, at any time, with or without notice. This cancellation shall be effective immediately or as may be specified in the notice and may include disabling your current and future access to DirectConnect. IMN may also suspend or terminate this Agreement if you invite other users with whom you do not know to connect; abuse the any DirectConnect messaging services; creating multiple or false profiles; infringe on any intellectual property rights, violating any provisions in this Agreement, disparage IMN or its executives, Board members, affiliates, staff or other related entities or persons, or exhibit any other behavior that IMN, in its sole discretion, deems contrary to the purpose of the website.

*No Waiver. Failure by either party to exercise any right or remedy under these Terms does not constitute a waiver of that right or remedy.

*Entire Agreement. These terms (including any terms incorporated by reference in these terms), constitute the entire agreement between you and us with respect to your access to and use of the website or receipt of any service and supersede all prior agreements, negotiations and discussions between you and us relating to the same.

*Law and Jurisdiction. Where you visit, register and/or subscribe to a this site or related service (as indicated on this website or otherwise notified to you), these terms (and any dispute or claim arising out of or in connection with these terms, including non-contractual disputes or claims), to the maximum extent permissible under the law of the territory that you are located in, will be governed by the laws of the State of New York. Any action to enforce these terms shall be brought in a federal court or a state court located in the state of New York, county of New York, and you agree to submit yourself to the personal jurisdiction of those courts in any such action.

*Force Majeure. We shall not be deemed to be in breach of these Terms by reason of any delay in performing, or any failure to perform any service or our obligations in relation to these Terms, if the delay or failure was due to any cause beyond our reasonable control, including but not limited to acts of God, explosions, floods, fire or accident, war or threat of war, terrorism or threat of terrorism, sabotage, civil disturbance, epidemics, prohibitions or measures of any kind on the part of any governmental, parliamentary or local authority, import or export regulations or embargoes, or industrial actions or trade disputes (whether involving our employees or of third parties).

*Severability. If any provision of these Terms is found to be wholly or partially invalid, void or unenforceable by any court having competent jurisdiction or by virtue of any legislation or any other reason, that provision shall be invalid, void or unenforceable to that extent only and no further and the validity and enforceability of the remaining provisions of these Terms shall not be affected.

*Notices. Any notice given pursuant to these Terms shall be made by email or first class post, in the case of you, to the address provided on your registration form and, in the case of us, to the address posted on the website or otherwise notified to you in relation to any relevant service. Any such notice shall be deemed to have arrived if sent by post within three (3) days of posting and if sent by email at the time of transmission.
Information Management Network - Privacy Notice

Introduction - Who we are

Euromoney Institutional Investor PLC (“Euromoney”, “we”, “us” or “our”) is an international business-information group covering asset management, price discovery, data and market intelligence, and banking and finance. The group also runs an extensive portfolio of events for the telecoms, financial and commodities markets.

For a full list of our brands and group companies, please click on this link. Euromoney and its group companies are committed to respecting the privacy of every person who visits, registers with or subscribes to our websites, publications, events and other products or services.

Euromoney is the primary data controller of personal data collected through this website or that we may collect in different ways as described in this Privacy Notice. If you are contacted by our other group companies, they will also be controllers of your personal data. This means that they are responsible for how your personal data is used, just as we are. You may contact any of these companies directly, or you can contact Euromoney by emailing or writing to the Data Protection Officer at Euromoney Institutional Investor PLC, 8 Bouverie Street, London EC4Y 8AX, United Kingdom.

This Privacy Notice was updated on 23 May 2018

Our Approach to Your Privacy

This Privacy Notice outlines the information we may collect about you in relation to your use of our products and services (“personal data”). It also explains the legal rights that you have in relation to your data and how you may exercise these rights.

Some of our group companies may collect and use personal data for different purposes; those companies have their own websites and privacy notices.

We will process your data for the following lawful purposes: with your consent; to fulfil our obligations to you; and where there is a legitimate interest to do so.

When possible, we rely on your consent to use your data for the purposes described in this Privacy Notice. We also process personal data to fulfil our contractual obligations to you, for example, when you register for any of our services, subscribe to a publication, sign-up for an event or purchase a product from us, we will need to process some of your personal data. This will also include details of the person/people responsible for payment (if different).

We may determine that processing your personal data serves both of our legitimate interests. This is the case in relation to many of our research, customer survey, sales, marketing and advertising activities described in this Privacy Notice. These activities allow us to better understand your requirements, which in turn enables us to provide you with a better service. We review the bases for our processing decisions carefully and you can object to these activities at any time (see the “Your Rights” section of this Privacy Notice).

What Personal Data We Collect & Why

Our primary goal in collecting personal data from you is to give you a relevant customised experience of our products and services.

  • Registration, Free Trials & Subscriptions

    When you register with our website and/or sign up for a free trial of our products or services, we may ask you to provide your name, address, email address and telephone number, and details relevant to your occupation or employer.

    If you subscribe to one of our products or services, we will also ask for payment details. Credit/debit card payments are processed using a third party supplier and we do not retain the credit card data (see the Third Party Sites of this Privacy Notice). Address details may be shared with third party service providers engaged by us for order fulfilment, delivery and payment collection. This personal data is used by us to complete subscription requests.

  • Events & Conferences

    If you have registered for an event through a group website we may collect personal data including: name, job title, company, address, telephone number and email.

    This information is necessary so that we can complete your registration for the event and provide you with relevant event materials.

    We may also provide delegate details (e.g. name, email) to event sponsors who, subject to your consent, may contact you for their own advertising and marketing purposes.

  • Advertising & Marketing

    We use the personal data you provide us and which we collect from you to inform you about similar products and services which we provide. We may send you marketing communications that are sponsored by our partners and which are targeted to your interests based on information you have provided us such as job title, employer and/or industry. If you have consented to receive information from other Euromoney group companies, we may share your personal data with these companies so that they can fulfil your request to receive marketing materials in accordance with your preferences. We will not share your personal data with any third parties for their own marketing purposes unless you have provided your consent.

    Each of the Euromoney group companies that may contact you is a data controller in relation to the personal data that you have agreed to share with them. If you have any questions or concerns, you may contact the individual company, or us – using the contact details set out in the “Who We Are” section.

    You can opt out from receiving such materials at any time.

    The personal data we may use for advertising and marketing purposes includes your name, email address, job title, phone number, company name/employer, geo location, postal address and data collected using cookies and other similar technology (Please read our separate Cookies Policy to find out more about which cookies we use, how they work and how you can control your cookie options).

    Marketing materials are sent electronically, by post and we may occasionally call you.

  • Online Targeted Advertising

    We use targeted advertising on our websites to display advertisements that are relevant to what we believe are your interests. In order to deliver relevant advertisements, we use third parties to deliver cookies that collect information about your IP address and how you interact with our sites (e.g. browsing information, which articles you have read etc.). This data is used by the third parties to determine which advertisements may be of interest to you.

    We may also share your personal data with third parties to deliver targeted advertising to you on other websites (e.g. Twitter Tailored Audiences or Facebook Custom Audiences). This could include your email address, cookie data, and information obtained from third parties. Third party cookies may also be used to enable us to target advertisements to you on other websites that you visit.

  • Lead Generation and Scoring

    We occasionally use the services of trusted third parties in order to ensure that the personal data we use for advertising and marketing purposes is accurate and up-to-date. To do this, we transfer personal data of individual leads (such as name, email, job title, location and phone number) to these third parties who conduct research to verify the data – primarily against public information.

    We also use algorithmic software technology to help us improve the quality and relevance of marketing activities. The personal data analysed by the software includes email address, phone number, job title, address, purchase history and account information. This allows us to provide meaningful offers that are relevant to your specific profile.

  • Surveys, Market Research & Customer Feedback

    We want to understand the needs of our readers and customers. We may therefore use the information you provide us – including your name and contact details – to contact you to request your feedback, or to participate in our customer and market research.

  • Public forums, message boards and blogs

    Some of the pages on our group websites may include message boards, blogs or other facilities for generating content from users. Any information that is disclosed in these areas becomes public information and you should always be careful when deciding to post any personal data. User generated content is also subject to our site Terms & Conditions.

  • Business or Asset Sale

    If we sell a business or assets we may need to disclose your personal data to the prospective buyer of such business or assets.

    If Euromoney, or any of our group companies is sold or sells our assets or is acquired by a third party, then personal data about our customers will be acquired by that third party. A transfer of your personal data in these circumstances would be necessary so that the services you have contracted for can still be delivered, or so that you can continue to enjoy the benefits of our free products and services. You will receive notice if a new controller assumes responsibility for your personal data.

  • Additional Third Party Disclosures

    We may disclose your personal data to other third parties in the following situations:

    • To third party partners who help us by providing services such as technology, marketing, advisory or other services. These third parties only receive encrypted data and may only process personal data to provide those services to us.
    • Where we are required by law or regulation to do so. In each case we will seek, where practicable, to minimise the amount of data that is disclosed.
    • If required to protect the rights and interests of other users and/or Euromoney and its affiliates (including our employees, agents and contractors), or as otherwise set out in our Terms & Conditions. This may include exchanging information with other companies and organisations for the purposes of fraud protection.
  • Email Tracking

    We may include small pixel tags (small image files) within the emails we send you in order to determine whether our emails are opened and/or whether the hyperlinks inside our emails are clicked through. We may also collect browser, location and the device used to engage with our email communications. This information allows us to better understand whether we are meeting our users’ needs and how we can improve our communications. No other information is collected. You can opt out of receiving our direct marketing emails either by following the instructions in each email, or by contacting us (see the “Who We Are” section of this Privacy Notice).

International Transfers

Some of the Euromoney group companies are based outside the European Economic Area (EEA). If you have consented to being contacted by our group companies, then the transfer of your personal data will be made according to the terms of an international data sharing agreement that contains obligations approved by European data protection regulators. Any of our group companies that receive your personal data will be co-controllers of that data, which means they may determine how they process your personal data – although they may only use it for the purposes for which it was shared, unless you are informed of new or additional processing activities.

We may also transfer personal data to third party service providers as described in this Privacy Notice which are located outside the EEA. Where we conduct these transfers, we take all steps necessary to ensure that your data is treated securely and in accordance with applicable privacy legislation, either by only sending your personal data to jurisdictions that provide an adequate degree of legal protection for your data or by imposing approved contractual terms on these third parties.

Retention Periods

We have a data retention policy that ensures we don’t use or store your personal data for longer than necessary. We consider the following issues to determine retention periods:

  • Guidance from the UK Information Commissioner or other regulatory agency, or industry best practice recommendations;
  • The business rationale for collection and expiry of the purpose for which personal data was collected;
  • Our ongoing ability to ensure the accuracy of the data; and
  • Legal and regulatory requirements.

We may occasionally need to keep personal data for either shorter or longer periods than specified in our retention policy. In such circumstances, application of the retention period to the data will be temporarily suspended. The suspension of an applicable retention period will be carried out in a manner that respects the rights and interests of all persons concerned.

How You Can Set Your Data & Privacy Preferences

You can use our Preference Centre to select the topics that are of interest to you so that we can send you publications and information about our products and services that are especially relevant to you. You can also choose the channels we use to contact you (email, phone, post, etc.) and can also opt-out of receiving marketing communications.

Your Rights

You have certain rights in relation to your personal data which include the following:

  • Access & Portability

    You may request access to any personal data of yours for which Euromoney is responsible as controller. Unless there are legal or regulatory reasons for not doing so, we will confirm whether we process any of your personal data and if we do, we will provide you with the following information: the purposes of the processing, the categories of personal data, any recipients of your personal data, the applicable retention period and the data source. Copies of your personal data will be made available to you in a structured, machine-readable format.

    You may also request that we transfer the personal data that you have submitted to us, to another controller, where it is technically feasible for us to do so.

    If you have consented to our processing of your personal data, or if we are processing your personal data in order to fulfil our contractual obligations to you, then you can submit a request that we transfer your personal data to another data controller.

  • Rectification, Restriction, Objection

    You have the right to request that Euromoney rectify any errors in the personal data that we process. In some circumstances, you may also be able to ask for the erasure of personal data, and/or request that the processing of your personal data be restricted. You may also object to the processing of your personal data for sales or marketing purposes.

  • How to Exercise Your Rights

    To exercise any of these rights, please contact us by post or email at the following addresses:

    Euromoney Institutional Investor PLC
    8 Bouverie Street
    London, EC4Y 8AX
    United Kingdom


    Web form: Complete Subject Data Request Form

    We may need to check your identity prior to processing a request.

    Euromoney will do our best to respond to any questions and address any of your concerns. You are also able to register any complaints regarding the processing of your personal data directly with the UK Information Commissioner.

Protecting Your Data

Euromoney is committed to keeping your personal data secure and we will take appropriate technical and organisational measures to protect your personal data from loss, unauthorised use, disclosure or destruction. Although we do our best to protect your personal data, we cannot guarantee that any transmission of data is without risk. We have therefore implemented information security policies and rules, staff training on information security, and technical measures to ensure the integrity of data that we have under our control.

All our employees, contractors and data processors (i.e. those third parties that process personal data on our behalf) are required to keep such data confidential and not to use it for any purpose other than the performance of services we have requested.

Third Party Sites

Our site may contain links to other websites – including, for example, providers of payment processing services. Euromoney is not responsible for the privacy and data collection practices of third party sites and we therefore recommend that you review the privacy policies and terms of service of each site you visit.

email already exists, please use "Forgot Password" page to reset a password for an existing account.
(Click "Reset Password" button below and email with password reset instruction will be emailed to you.)

Reset Password